Literature DB >> 28549192

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

Eoghan M McCarthy1, Emily Sutton2, Stephanie Nesbit2, Ben Parker1,3, David Jayne4, Bridget Griffiths5, David A Isenberg6, Anisur Rahman6, Caroline Gordon7,8, David P D'Cruz9, Benjamin Rhodes10, Peter Lanyon11, Edward M Vital12,13, Chee-Seng Yee14, Christopher J Edwards15,16, Lee-Suan Teh17, Mohammed Akil18, Neil J McHugh19,20, Asad Zoma21, Ian N Bruce1,2.   

Abstract

Entities:  

Year:  2017        PMID： 28549192      PMCID： PMC6790502          DOI： 10.1093/rheumatology/kex218

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  1 in total

1.  Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.

Authors:  Toni Maslen; Ian N Bruce; David D'Cruz; Mihaela Ianosev; Damon L Bass; Christel Wilkinson; David A Roth
Journal:  Lupus Sci Med       Date:  2021-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.